Skip to main content
Top
Published in: Annals of Hematology 8/2008

01-08-2008 | Original Article

Fluorine-18 fluorodeoxyglucose positron emission tomography in mature T-cell and natural killer cell malignancies

Authors: Pek-Lan Khong, Clara B. Y. Pang, Raymond Liang, Yok-Lam Kwong, Wing-Yan Au

Published in: Annals of Hematology | Issue 8/2008

Login to get access

Abstract

Fluorine-18 fluorodeoxyglucose (FDG)-positron emission tomography (PET) is useful in Hodgkin and B-cell lymphomas. Few data exist on T-cell and natural killer (NK)-cell lymphomas. Thirty consecutive T-cell and NK-cell lymphomas were investigated with PET-computerized tomography (CT). In 12 NK-cell lymphomas, all nasal/extranasal lesions were FDG-avid. In nasal/maxillary areas, FDG-avid tumours were consistently more localised than on CT, suggesting that soft tissue masses on CT were partly due to inflammation. These findings have important implications in radiotherapy planning. In two NK-cell lymphomas, PET did not detect morphologically occult marrow infiltration uncovered by in situ hybridisation for Epstein–Barr-virus-encoded small RNA. In angioimmunoblastic lymphoma (n = 7), peripheral T-cell lymphoma, unspecified (PTCL-U, n = 4) and anaplastic large cell lymphoma (ALCL, n = 3), involved nodal/extranodal sites shown on CT and/or biopsy were concordantly PET-positive. In one PTCL-U, PET detected FDG-avid marrow infiltrations not shown on biopsies. In contrast, cutaneous ALCL (n = 1) and mycosis fungoides (n = 2) showed minimal FDG uptake. In one case of T-cell large granular lymphocyte leukaemia, marrow, nodal and bowel infiltrations were not FDG-avid. PET maximum standardised uptake value did not correlate with clinicopathological features and prognosis. These observations defined the pre-treatment value of PET-CT in T-cell and NK-cell lymphomas. The post-treatment role requires further studies.
Literature
1.
go back to reference Isasi CR, Lu P, Blaufox MD (2005) A metaanalysis of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography in the staging and restaging of patients with lymphoma. Cancer 104:1066–1074PubMedCrossRef Isasi CR, Lu P, Blaufox MD (2005) A metaanalysis of 18F-2-deoxy-2-fluoro-D-glucose positron emission tomography in the staging and restaging of patients with lymphoma. Cancer 104:1066–1074PubMedCrossRef
2.
go back to reference Zijlstra JM, Lindauer-van der Werf G, Hoekstra OS, Hooft L, Riphagen II, Huijgens PC (2006) 18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review. Haematologica 91:522–529PubMed Zijlstra JM, Lindauer-van der Werf G, Hoekstra OS, Hooft L, Riphagen II, Huijgens PC (2006) 18F-fluoro-deoxyglucose positron emission tomography for post-treatment evaluation of malignant lymphoma: a systematic review. Haematologica 91:522–529PubMed
3.
go back to reference Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, Wiseman GA, Kostakoglu L, Scheidhauer K, Buck A, Naumann R, Spaepen K, Hicks RJ, Weber WA, Reske SN, Schwaiger M, Schwartz LH, Zijlstra JM, Siegel BA, Cheson BD, Imaging Subcommittee of International Harmonization Project in Lymphoma (2007) Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 25:571–578PubMedCrossRef Juweid ME, Stroobants S, Hoekstra OS, Mottaghy FM, Dietlein M, Guermazi A, Wiseman GA, Kostakoglu L, Scheidhauer K, Buck A, Naumann R, Spaepen K, Hicks RJ, Weber WA, Reske SN, Schwaiger M, Schwartz LH, Zijlstra JM, Siegel BA, Cheson BD, Imaging Subcommittee of International Harmonization Project in Lymphoma (2007) Use of positron emission tomography for response assessment of lymphoma: consensus of the Imaging Subcommittee of International Harmonization Project in Lymphoma. J Clin Oncol 25:571–578PubMedCrossRef
4.
go back to reference Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V, The International Harmonization Project on Lymphoma (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25:579–586PubMedCrossRef Cheson BD, Pfistner B, Juweid ME, Gascoyne RD, Specht L, Horning SJ, Coiffier B, Fisher RI, Hagenbeek A, Zucca E, Rosen ST, Stroobants S, Lister TA, Hoppe RT, Dreyling M, Tobinai K, Vose JM, Connors JM, Federico M, Diehl V, The International Harmonization Project on Lymphoma (2007) Revised response criteria for malignant lymphoma. J Clin Oncol 25:579–586PubMedCrossRef
5.
go back to reference Advani R, Maeda L, Lavori P, Quon A, Hoppe R, Breslin S, Rosenberg SA, Horning SJ (2007) Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin’s disease. J Clin Oncol 25:3902–3907PubMedCrossRef Advani R, Maeda L, Lavori P, Quon A, Hoppe R, Breslin S, Rosenberg SA, Horning SJ (2007) Impact of positive positron emission tomography on prediction of freedom from progression after Stanford V chemotherapy in Hodgkin’s disease. J Clin Oncol 25:3902–3907PubMedCrossRef
6.
go back to reference Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M, Patti C, Loft A, Di Raimondo F, D’Amore F, Biggi A, Vitolo U, Stelitano C, Sancetta R, Trentin L, Luminari S, Iannitto E, Viviani S, Pierri I, Levis A (2007) Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 25:3746–3752PubMedCrossRef Gallamini A, Hutchings M, Rigacci L, Specht L, Merli F, Hansen M, Patti C, Loft A, Di Raimondo F, D’Amore F, Biggi A, Vitolo U, Stelitano C, Sancetta R, Trentin L, Luminari S, Iannitto E, Viviani S, Pierri I, Levis A (2007) Early interim 2-[18F]fluoro-2-deoxy-D-glucose positron emission tomography is prognostically superior to international prognostic score in advanced-stage Hodgkin’s lymphoma: a report from a joint Italian-Danish study. J Clin Oncol 25:3746–3752PubMedCrossRef
7.
go back to reference Au WY, Ma SY, Chim CS, Choy C, Loong F, Lie AK, Lam CC, Leung AY, Tse E, Yau CC, Liang R, Kwong YL (2005) Clinicopathologic features and treatment outcome of mature T-cell and natural killer-cell lymphomas diagnosed according to the World Health Organization classification scheme: a single center experience of 10 years. Ann Oncol 16:206–214PubMedCrossRef Au WY, Ma SY, Chim CS, Choy C, Loong F, Lie AK, Lam CC, Leung AY, Tse E, Yau CC, Liang R, Kwong YL (2005) Clinicopathologic features and treatment outcome of mature T-cell and natural killer-cell lymphomas diagnosed according to the World Health Organization classification scheme: a single center experience of 10 years. Ann Oncol 16:206–214PubMedCrossRef
8.
go back to reference Jaffe ES, Harris NL, Stein H, Vardiman Je (2001) Pathology and genetics of tumours of haematopoietic and lympohid tissue. Tumours of haematopoietic and lymphoid tissues, World health organization classfication of tumours. IARC, Lyon, pp 121–253 Jaffe ES, Harris NL, Stein H, Vardiman Je (2001) Pathology and genetics of tumours of haematopoietic and lympohid tissue. Tumours of haematopoietic and lymphoid tissues, World health organization classfication of tumours. IARC, Lyon, pp 121–253
9.
go back to reference Ho JW, Ho FC, Chan AC, Liang RH, Srivastava G (1998) Frequent detection of Epstein-Barr virus-infected B cells in peripheral T-cell lymphomas. J Pathol 185:79–85PubMedCrossRef Ho JW, Ho FC, Chan AC, Liang RH, Srivastava G (1998) Frequent detection of Epstein-Barr virus-infected B cells in peripheral T-cell lymphomas. J Pathol 185:79–85PubMedCrossRef
10.
go back to reference Au WY, Pang A, Choy C, Chim CS, Kwong YL (2004) Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients. Blood 104:243–249PubMedCrossRef Au WY, Pang A, Choy C, Chim CS, Kwong YL (2004) Quantification of circulating Epstein-Barr virus (EBV) DNA in the diagnosis and monitoring of natural killer cell and EBV-positive lymphomas in immunocompetent patients. Blood 104:243–249PubMedCrossRef
11.
go back to reference Wong KF, Chan JK, Cheung MM, So JC (2001) Bone marrow involvement by nasal NK cell lymphoma at diagnosis is uncommon. Am J Clin Pathol 115:266–270PubMedCrossRef Wong KF, Chan JK, Cheung MM, So JC (2001) Bone marrow involvement by nasal NK cell lymphoma at diagnosis is uncommon. Am J Clin Pathol 115:266–270PubMedCrossRef
12.
go back to reference Elstrom R, Guan L, Baker G, Nakhoda K, Vergilio JA, Zhuang H, Pitsilos S, Bagg A, Downs L, Mehrotra A, Kim S, Alavi A, Schuster SJ (2003) Utility of FDG-PET scanning in lymphoma by WHO classification. Blood 101:3875–3876PubMedCrossRef Elstrom R, Guan L, Baker G, Nakhoda K, Vergilio JA, Zhuang H, Pitsilos S, Bagg A, Downs L, Mehrotra A, Kim S, Alavi A, Schuster SJ (2003) Utility of FDG-PET scanning in lymphoma by WHO classification. Blood 101:3875–3876PubMedCrossRef
13.
go back to reference Tsai EY, Taur A, Espinosa L, Quon A, Johnson D, Dick S, Chow S, Advani R, Warnke R, Kohler S, Hoppe RT, Kim YH (2006) Staging accuracy in mycosis fungoides and sezary syndrome using integrated positron emission tomography and computed tomography. Arch Dermatol 142:577–584PubMedCrossRef Tsai EY, Taur A, Espinosa L, Quon A, Johnson D, Dick S, Chow S, Advani R, Warnke R, Kohler S, Hoppe RT, Kim YH (2006) Staging accuracy in mycosis fungoides and sezary syndrome using integrated positron emission tomography and computed tomography. Arch Dermatol 142:577–584PubMedCrossRef
14.
go back to reference Kako S, Izutsu K, Ota Y, Minatani Y, Sugaya M, Momose T, Ohtomo K, Kanda Y, Chiba S, Motokura T, Kurokawa M (2007) FDG-PET in T-cell and NK-cell neoplasms. Ann Oncol 18:1685–1690PubMedCrossRef Kako S, Izutsu K, Ota Y, Minatani Y, Sugaya M, Momose T, Ohtomo K, Kanda Y, Chiba S, Motokura T, Kurokawa M (2007) FDG-PET in T-cell and NK-cell neoplasms. Ann Oncol 18:1685–1690PubMedCrossRef
15.
go back to reference Chim CS, Ma SY, Au WY, Choy C, Lie AK, Liang R, Yau CC, Kwong YL (2004) Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index. Blood 103:216–221PubMedCrossRef Chim CS, Ma SY, Au WY, Choy C, Lie AK, Liang R, Yau CC, Kwong YL (2004) Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index. Blood 103:216–221PubMedCrossRef
16.
17.
go back to reference Cheung MM, Chan JK, Lau WH, Ngan RK, Foo WW (2002) Early stage nasal NK/T-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality. Int J Radiat Oncol Biol Phys 54:182–190PubMed Cheung MM, Chan JK, Lau WH, Ngan RK, Foo WW (2002) Early stage nasal NK/T-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality. Int J Radiat Oncol Biol Phys 54:182–190PubMed
18.
go back to reference Ooi GC, Chim CS, Liang R, Tsang KW, Kwong YL (2000) Nasal T-cell/natural killer cell lymphoma: CT and MR imaging features of a new clinicopathologic entity. AJR Am J Roentgenol 174:1141–1145PubMed Ooi GC, Chim CS, Liang R, Tsang KW, Kwong YL (2000) Nasal T-cell/natural killer cell lymphoma: CT and MR imaging features of a new clinicopathologic entity. AJR Am J Roentgenol 174:1141–1145PubMed
19.
go back to reference Schoder H, Noy A, Gonen M, Weng L, Green D, Erdi YE, Larson iSM, Yeung HW (2005) Intensity of 18fluorodeoxyglucose uptake n positron emission tomography distinguishes between indolent and aggressive non-Hodgkin’s lymphoma. J Clin Oncol 23:4643–4651PubMedCrossRef Schoder H, Noy A, Gonen M, Weng L, Green D, Erdi YE, Larson iSM, Yeung HW (2005) Intensity of 18fluorodeoxyglucose uptake n positron emission tomography distinguishes between indolent and aggressive non-Hodgkin’s lymphoma. J Clin Oncol 23:4643–4651PubMedCrossRef
20.
go back to reference Jerusalem G, Beguin Y, Najjar F, Hustinx R, Fassotte MF, Rigo P, fillet G (2001) Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin’s lymphoma (NHL). Ann Oncol 12:825–830PubMedCrossRef Jerusalem G, Beguin Y, Najjar F, Hustinx R, Fassotte MF, Rigo P, fillet G (2001) Positron emission tomography (PET) with 18F-fluorodeoxyglucose (18F-FDG) for the staging of low-grade non-Hodgkin’s lymphoma (NHL). Ann Oncol 12:825–830PubMedCrossRef
21.
go back to reference Pakos EE, Fotopoulos AD, Ioannidis JP (2005) 18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis. J Nucl Med 46:958–963PubMed Pakos EE, Fotopoulos AD, Ioannidis JP (2005) 18F-FDG PET for evaluation of bone marrow infiltration in staging of lymphoma: a meta-analysis. J Nucl Med 46:958–963PubMed
22.
go back to reference Lee J, Suh C, Huh J, Jun HJ, Kim K, Jung C, Park K, Park YH, Ko YH, Kim WS (2007) Effect of positive bone marrow EBV in situ hybridization in staging and survival of localized extranodal natural killer/T-cell lymphoma, nasal-type. Clin Cancer Res 13:3250–3254PubMedCrossRef Lee J, Suh C, Huh J, Jun HJ, Kim K, Jung C, Park K, Park YH, Ko YH, Kim WS (2007) Effect of positive bone marrow EBV in situ hybridization in staging and survival of localized extranodal natural killer/T-cell lymphoma, nasal-type. Clin Cancer Res 13:3250–3254PubMedCrossRef
23.
go back to reference Hutchings M, Loft A, Hansen M, Pedersen LM, Buhl T, Jurlander J, Buus S, Keiding S, D’Amore F, Boesen AM, Berthelsen AK, Specht L (2006) FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 107:52–59PubMedCrossRef Hutchings M, Loft A, Hansen M, Pedersen LM, Buhl T, Jurlander J, Buus S, Keiding S, D’Amore F, Boesen AM, Berthelsen AK, Specht L (2006) FDG-PET after two cycles of chemotherapy predicts treatment failure and progression-free survival in Hodgkin lymphoma. Blood 107:52–59PubMedCrossRef
24.
go back to reference Newman JS, Francis IR, Kaminski MS, Wahl RL (1994) Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT. Radiology 190:111–116PubMed Newman JS, Francis IR, Kaminski MS, Wahl RL (1994) Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT. Radiology 190:111–116PubMed
25.
go back to reference Lapela M, Leskinen S, Minn HR, Lindholm P, Klemi PJ, Söderström KO, Bergman J, Haaparanta M, Ruotsalainen U, Solin O, Joensuu H (1995) Increased glucose metabolism in untreated non-Hodgkin’s lymphoma: a study with positron emission tomography and fluorine-18-fluorodeoxyglucose. Blood 86:3522–3527PubMed Lapela M, Leskinen S, Minn HR, Lindholm P, Klemi PJ, Söderström KO, Bergman J, Haaparanta M, Ruotsalainen U, Solin O, Joensuu H (1995) Increased glucose metabolism in untreated non-Hodgkin’s lymphoma: a study with positron emission tomography and fluorine-18-fluorodeoxyglucose. Blood 86:3522–3527PubMed
26.
go back to reference Larson SM, Erdi Y, Akhurst T, Mazumdar M, Macapinlac HA, Finn RD, Casilla C, Fazzari M, Srivastava N, Yeung HW, Humm JL, Guillem J, Downey R, Karpeh M, Cohen AE, Ginsberg R (1999) Tumor Treatment Response Based on Visual and Quantitative Changes in Global Tumor Glycolysis Using PET-FDG Imaging. The Visual Response Score and the Change in Total Lesion Glycolysis. Clin Positron Imaging 2:159–171PubMedCrossRef Larson SM, Erdi Y, Akhurst T, Mazumdar M, Macapinlac HA, Finn RD, Casilla C, Fazzari M, Srivastava N, Yeung HW, Humm JL, Guillem J, Downey R, Karpeh M, Cohen AE, Ginsberg R (1999) Tumor Treatment Response Based on Visual and Quantitative Changes in Global Tumor Glycolysis Using PET-FDG Imaging. The Visual Response Score and the Change in Total Lesion Glycolysis. Clin Positron Imaging 2:159–171PubMedCrossRef
Metadata
Title
Fluorine-18 fluorodeoxyglucose positron emission tomography in mature T-cell and natural killer cell malignancies
Authors
Pek-Lan Khong
Clara B. Y. Pang
Raymond Liang
Yok-Lam Kwong
Wing-Yan Au
Publication date
01-08-2008
Publisher
Springer-Verlag
Published in
Annals of Hematology / Issue 8/2008
Print ISSN: 0939-5555
Electronic ISSN: 1432-0584
DOI
https://doi.org/10.1007/s00277-008-0494-8

Other articles of this Issue 8/2008

Annals of Hematology 8/2008 Go to the issue
Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Watch this official video from ACC.24. Dr. Biykem Bozkurt discuss last year's major advances in heart failure and cardiomyopathies.